Combining Gemcitabine With CXCR4, PD-1 Inhibitors for Pancreatic Ductal Adenocarcinoma

Gulam Abbas Manji, MD, PhD, expands on the combination treatment of CXCR4 and PD-1 inhibitors for pancreatic ductal adenocarcinoma and how recent research in lab mice has pointed to its potential benefit.

He describes the CXCL12-CXCR4 chemokine axis and how its disruption can lead to increased activation of CD8+ T cells.

Dr. Manji serves as the Director of Pancreas Medical Oncology and Director of GI Medical Oncology at Columbia University Irving Medical Center.

View his further comments on the ARC-8 study on novel CD73 inhibitor quemliclustat.